We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

59 hedge funds and large institutions have $138M invested in Orchestra BioMed in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

11% more funds holding

Funds holding: 53 → 59 (+6)

7% more capital invested

Capital invested by funds: $129M → $138M (+$8.57M)

6.04% more ownership

Funds ownership: 62.75% → 68.8% (+6%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
59
Holders Change
+6
Holders Change %
+11.32%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
10
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Saba Capital Management
New York
+$7.28M
2
SC
Sculptor Capital
New York
+$4.85M
3
RCM
Radcliffe Capital Management
Pennsylvania
+$4.02M
4
CC
Centiva Capital
New York
+$3.31M
5
WRBC
W.R. Berkley Corp
Connecticut
+$1.98M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$7.5M
2
O
OrbiMed
New York
-$5.04M
3
KPF
K2 Principal Fund
Ontario, Canada
-$4.29M
4
M
Murchinson
Ontario, Canada
-$1.97M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
51
Altium Capital Management
New York
$99K – – –
CM
52
Cohanzick Management
New York
$99K – – –
RCM
53
Rivernorth Capital Management
Florida
$99K – – –
LWA
54
Lenox Wealth Advisors
New York
$20K – – –
TRCT
55
Tower Research Capital (TRC)
New York
$11K +$8.77K +888 +451%
Morgan Stanley
56
Morgan Stanley
New York
$7K – – –
CCM
57
Context Capital Management
California
$3K +$3.04K +308 New
ASM
58
ATW SPAC Management
New York
$1.9K +$341K +34,500 +22%
UBS Group
59
UBS Group
Switzerland
$1K +$563 +57 New
PI
60
Putnam Investments
Massachusetts
– -$7.5M -750,000 Closed
O
61
OrbiMed
New York
– -$5.04M -500,000 Closed
KPF
62
K2 Principal Fund
Ontario, Canada
– -$4.29M -425,541 Closed
Wellington Management Group
63
Wellington Management Group
Massachusetts
– -$1.13M -113,052 Closed
WAM
64
Wolverine Asset Management
Illinois
– -$198K -19,719 Closed
BCM
65
Basso Capital Management
Connecticut
– -$106K -10,500 Closed
PCM
66
Pinz Capital Management
New York
– -$65K -6,400 Closed
AA
67
Ancora Advisors
Ohio
– -$54K -5,400 Closed
1 2
3

OBIO Hedge Fund Activity: Q1 2022 in Review

59 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2022, worth a combined $138M — up 6.6% from $129M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OBIO positions and 8 closed out — a net gain of 6 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was Saba Capital Management, opening a new position worth an estimated $7.28M. The largest seller was Putnam Investments, exiting entirely with an estimated $7.5M sold.

  • 59 institutional investors held Orchestra BioMed (OBIO) as of Q1 2022, up from 53 in Q4 2021.
  • Funds reported $138M of Orchestra BioMed stock for Q1 2022, up 6.6% quarter-over-quarter.
  • 14 funds opened new Orchestra BioMed positions in Q1 2022 and 8 closed out, a net change of +6 holders.
  • The largest Orchestra BioMed buyer in Q1 2022 was Saba Capital Management, an estimated $7.28M added.
  • The largest Orchestra BioMed seller in Q1 2022 was Putnam Investments, an estimated $7.5M sold.

Based on aggregated 13F filings for Q1 2022.